Ezabenlimab
- Generic Name
- Ezabenlimab
- Drug Type
- Biotech
- CAS Number
- 2249882-54-8
- Unique Ingredient Identifier
- 5V1UI86573
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
- Conditions
- Myxofibrosarcoma (MFS)Advanced Soft Tissue SarcomaUndifferentiated Pleomorphic Sarcoma (UPS)
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT06370871
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
- Conditions
- Gastrointestinal CancerLung CancerPancreatic CancerColorectal CancerHead and Neck CancerLiver Cancer
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 70
- Registration Number
- NCT06091930
- Locations
- 🇨🇳
Shandong Cancer Hospital, Jinan, China
🇨🇳Shanghai East Hospital, Shanghai, China
🇯🇵National Cancer Center Hospital East, Chiba, Kashiwa, Japan
Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures
- Conditions
- Adult Soft Tissue SarcomaBiliary Tract CancerNon Small Cell Lung CancerColorectal CancerTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Institut Bergonié
- Target Recruit Count
- 120
- Registration Number
- NCT06084689
- Locations
- 🇫🇷
CHRU Poitiers, Poitiers, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷Institut Bergonié, Bordeaux, France
A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
- Conditions
- Neuroendocrine NeoplasmsSmall Cell Lung Carcinoma (SCLC)
- Interventions
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 45
- Registration Number
- NCT05879978
- Locations
- 🇫🇷
INS Claudius Regaud IUCT-Oncopole, Toulouse, France
🇧🇪Brussels - UNIV Saint-Luc, Bruxelles, Belgium
🇫🇷CTR François Baclesse, Caen, France
A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02)
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Amal Therapeutics
- Target Recruit Count
- 85
- Registration Number
- NCT05846516
- Locations
- 🇺🇸
USC/Norris Comprehensive Center, Los Angeles, California, United States
🇺🇸University of California Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 66
- Registration Number
- NCT05471856
- Locations
- 🇯🇵
Saitama Medical University International Medical Center, Saitama, Hidaka, Japan
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2
- Registration Number
- NCT05446129
- Locations
- 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT05327946
- Locations
- 🇺🇸
Florida Cancer Specialists-Sarasota-61670, Sarasota, Florida, United States
🇺🇸John Theurer Cancer Center, Hackensack, New Jersey, United States
🇨🇦Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, Canada
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Interventions
- Other: Investigator´s Choice Chemotherapy
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT05249426
- Locations
- 🇲🇩
ARENSIA Exploratory Medicine, Chisinau, Moldova, Republic of
🇵🇱Mandziuk Slawomir Specialist Medical Practice, Lublin, Poland
🇷🇴"Prof. Dr. Alexandru Trestioreanu" Oncology Institut, Bucharest, Romania
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
- Conditions
- Carcinoma, Squamous Cell of Head and Neck (HNSCC)MelanomaNon-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13
- Registration Number
- NCT05068102
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.